Plexin D1 expression is induced on tumor vasculature and tumor cells: A novel tarqet for diagnosis and therapy?

Cancer Research

Volumn 65, Issue 18, 2005, Pages 8317-8323

  Roodink, Ilse ^a   Raats, Jos ^b   Van Der Zwaag, Bert ^a   Verrijp, Kiek ^a   Kusters, Benno ^a   Van Bokhoven, Hans ^a   Linkels, Marianne ^a   De Waal, Robert M W ^a   Leenders, William P J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLEXIN; PLEXIN D1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MELANOMA; NERVE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR VASCULARIZATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; BACTERIOPHAGES; BRAIN NEOPLASMS; CAMELIDS, NEW WORLD; CELL ADHESION MOLECULES, NEURONAL; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; NERVE TISSUE PROTEINS; RNA;

EID: 24944581963     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4366     Document Type: Article

References (39)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
3. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 1999;13:9-22.
4. Blancher C, Moore JW, Robertson N, Harris AL. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1α, HIF-2α, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res 2001;61:7349-55.
5. Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000;14:391-6.
6. Leenders WP. Targetting VEGF in anti-angiogenic and anti-tumour therapy: where are we now? Int J Exp Pathol 1998;79:339-46.
7. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 Inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-55.
8. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
9. Eichhorn ME, Strieth S, Dellian M. Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. Drug Resist Updat 2004;7:125-38.
10. Vermeulen PB, Colpaert C, Salgado R, et al. Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J Pathol 2001;195:336-42.
11. Dome B, Paku S, Somlai B, Timar J. Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. J Pathol 2002;197:355-62.
12. Leenders W, Kusters B, De Waal R. Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 2002;9:83-7.
13. Kusters B, Leenders WP, Wesseling P, et al. Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res 2002;62:341-5.
14. Leenders W, Kusters B, Pikkemaat J, et al. Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in Gd-DTPA-enhanced MRI. Int J Cancer 2003;105:437-43.
15. Leenders WP. Kusters B, Verrijp K, et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 2004;10:6222-30.
16. Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003;9:571-9.
17. Castellani P, Borsi L, Carnemolla B, et al. Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol 2002;161:1695-700.
18. Posey JA, Khazaeli MB, DelGrosso A, et al. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti α v β 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 2001;16:125-32.
19. Balza E, Castellani P, Zijlstra A, et al. Lack of specificity of endoglin expression for tumor blood vessels. Int J Cancer 2001;94:579-85.
20. Tamagnone L, Artigiani S, Chen H, et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 1999;39:71-80.
21. Fujisawa H. Discovery of semaphorin receptors, neuropilin and plexin, and their functions in neural development. J Neurobiol 2004;59:24-33.
22. Pasterkamp RJ, Kolodkin AL. Semaphorin junction: making tracks toward neural connectivity. Curr Opin Neurobiol 2003;13:79-89.
23. Takahashi T, Fournier A, Nakamura F, et al. Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 1999;99:59-69.
24. van der Zwaag B, Hellemons AJ, Leenders WP, et al. PLEXIN-D1, a novel plexin family member, is expressed in vascular endothelium and the central nervous system during mouse embryogenesis. Dev Dyn 2002;225:336-43.
25. Torres-Vazquez J, Gitler AD, Fraser SD, et al. Semaphorin-plexln signaling guides patterning of the developing vasculature. Dev Cell 2004;7:117-23.
26. Gitler AD. Lu MM. Epstein JA, Plexin DI and Semaphorin signaling are required in endothelial cells for cardiovascular development. Dev Cell 2004;7:107-16.
27. Gu C, Yoshida Y, Livet J, et al. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 2005;307:265-8.
28. Kusters B, de Waal RM, Wesseling P, et al. Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma Cancer Res 2003;63:5408-13.
29. Raats JM, Wijnen EM, Pruijn GJ. van den Hoogen FH, van Venrooij WJ. Recombinant human monoclonal autoantibodies specific for citrulline-containing peptides from phage display libraries derived from patients with rheumatoid arthritis. J Rheumatol 2003;30:1696-711.
30. van Koningsbruggen S, de Haard H, de Kievit P, et al. Llama-derived phage display antibodies in the dissection of the human disease oculopharyngeal muscular dystrophy. J Immunol Methods 2003;279:149-61.
31. Kreis TE. Microinjected antibodies against the cytoplasmic domain of vesicular stomatitis virus glycoprotein block its transport to the cell surface. Embo J 1986;5:931-41.
32. Kristensen P, Winter G. Proteolytic selection for protein folding using filamentous bacteriophages. Fold Des 1998;3:321-8.
33. Raats J, van Bree N, van Woezik J, Pruijn G. Generating recombinant anti-idiotypic antibodies for the detection of haptens in solution. J Immunoassay Immunochem 2003;24:115-46.
34. Kusters B, Westphal JR, Smits D, et al. The pattern of metastasis of human melanoma to the central nervous system is not influenced by integrin α(v)β(3) expression. Int J Cancer 2001;92:176-80.
35. Nakamura F, Kalb RG, Strittmatter SM. Molecular basis of semaphorin-mediated axon guidance. J Neurobiol 2000;44:219-29.
36. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001;61:4750-5.
37. Horton MA. Arg-gly-Asp (RGD) peptides and pepti-domimetics as therapeutics: relevance for renal diseases. Exp Nephrol 1999;7:178-84.
38. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled α(v)β(3) integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146-51.
39. Christensen CR, Klingelhofer J, Tarabykina S, et al. Transcription of a novel mouse semaphorin gene, M-semaH, correlates with the metastatic ability of mouse tumor cell lines. Cancer Res 1998;58:1238-44.